Global Hypoparathyroidism Treatment Market: Snapshot
The rare condition named hypoparathyroidism involves the reduction in the activity parathyroid glands. The most common way a patient can suffer from hypoparathyroidism is after the parathyroid glands get removed or damaged during surgery. It is a state of low parathyroid hormone secretion and can cause a severe drop in calcium levels in the blood as well as high levels of phosphorus in the blood. Symptoms for hypoparathyroidism range from mild tingling in fingers, hands, or the mouth, to more serious and painful muscle cramps. Very rare symptoms exhibited by patients include convulsions and extreme muscle cramping of the whole body. The two forms of hypoparathyroidism include the deficiency of PTH due to low secretion, and PTH not being able to elicit a response from the bones and kidneys.
Read Report Overview:
Some of the more common treatments of hypoparathyroidism include supplementing the body with vitamins and minerals to normalize the levels of calcium and phosphorus in the blood. This includes the oral consumption of calcium carbonate tablets or the intake of high doses of vitamin D. The latter involves the consumption of calcitriol and works by enabling a better calcium absorption rate of the body. Another treatment option involves the administration of PTH using an FDA approved daily injection.
Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the level of calcium is little in blood and the phosphorus is high, due to which the human body show some sign which include muscle spasm, hair loss, dry skin, numbness, and seizures. Hypoparathyroidism occurs in both child and adults. If Hypoparathyroidism occurs in child it show some sign as poor tooth development, vomiting, headaches and mental disorders.
The present of Hypoparathyroidism in the body can be exam various test like PTH blood test, calcium blood test, also by ECG to check abnormal heart rhythm and also by CT scan to exam the deposition of calcium in brain. Hypoparathyroidism are most common problem now a days due to the lifestyle and eating habits.
Hypoparathyroidism Treatment Market: Drivers and Restraints
Hypoparathyroidism treatment market is estimated to be a big market over the forecast periods, as the current population over the globe are suffering from hypoparathyroidism, For instance, a report published by Endocrine Society in 2016, it was 60-8,000 patients in the U.S are suffering from hypoparathyroidism. Players are coming with new technology advancement for the treatment of hypoparathyroidism, For instance, in January 2015, Shire-NPS Pharmaceuticals, Inc. got approval from a product used for treatment of hypoparathyroidism name as NATPARA (parathyroid hormone) which is an injection for subcutaneous use. Current market are having less players which are working on hypoparathyroidism treatment. All the product in hypoparathyroidism come under pharmaceutical or directly connect to human, so it need to go under some clinical process and have to get the approval from the respective agency before going to commercializes in the market which is a restraints for the segment.
Hypoparathyroidism Treatment Market: Overview
Hypoparathyroidism treatment market have huge potentials for all the players are working or willing to work to come up with new product in this segments. For instance, in first quarter of 2015, Shire has purchased NPS Pharma in $5.2 Billion due to the product name as Natpara an injection used for the treatment of hypoparathyroidism. The population with hypoparathyroidism also show the high interest rate for getting the treatment. For instance, based on the publication by European Union (EU 28) in June 2016, less the 5 in 10,000 peoples in Europe Union is affected by hypoparathyroidism, which will be equivalent to total of fewer than 257,000 peoples. Many players also in process to make enters with their products into the market, as instance EnteraBio Ltd., is positively received an opinion in Europe market, and also currently focusing in the U.S.
Hypoparathyroidism Treatment Market: Region-wise Outlook
Geographically, Hypoparathyroidism Treatment Market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan, Middle East and Africa. North America will be the potential market for the players as there is huge demand for the product, and the players are also coming with new product with proper FDA approval. Europe and Asia-Pacific is also a market where the players grow as the potentials.
Request Brochure of the Report:
Hypoparathyroidism Treatment Market: Key Players
Some of the players for Hypoparathyroidism Treatment Market are Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, EnteraBio Ltd., WCCT GLOBAL INC., Takeda Pharmaceutical Company Limited, Novartis AG, and GlaxoSmithKline plc.
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453